Cathie Wood's ARK ETFs have made their daily trades public for Monday, July 8, 2024, showcasing strategic adjustments across several sectors. The most significant move was the purchase of 185155 shares of INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), with a total dollar value of $4,214,127, indicating a bullish stance on the biotechnology company. This trade was split across the ARKK and ARKG ETFs, with the former acquiring 163542 shares and the latter 21613 shares.
Following this, ARK also increased its bet on RECURSION PHARMACEUTICALS INC (NASDAQ:RXRX) by buying 423487 shares, divided into 363448 for ARKK and 60039 for ARKG, amounting to a total value of $3,099,924. This move comes after a series of consistent buys in previous days, suggesting a growing confidence in the pharmaceutical firm's prospects.
In addition, ARK bought 190770 shares of PACIFIC BIOSCIENCES OF CALIFORNIA INC (NASDAQ:PACB), valued at $249,908, split between ARKK and ARKG ETFs, and 15766 shares of PERSONALIS INC (NASDAQ:PSNL) through its ARKG ETF, with a total dollar value of $24,121.
On the sell side, ARK offloaded 27886 shares of INCYTE CORP (NASDAQ:INCY) through its ARKG ETF for $1,598,704, and 3084 shares of AEROVIRONMENT INC (NASDAQ:AVAV) through its ARKQ ETF, totaling $520,887. The sale of AEROVIRONMENT INC shares continues a selling trend observed in the previous trading sessions.
Lastly, ARK reduced its position in VERVE THERAPEUTICS INC (NASDAQ:VERV) by selling 12900 shares across the ARKK and ARKG ETFs, with a combined value of $67,725.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.